Recombinant MS4A1 (Rituximab Biosimilar) anticorps

N° du produit ABIN7487776

Cet anticorps anti-MS4A1 (Rituximab Biosimilar) est un anticorps Monoclonal produit chez le Mammalian Cells, détectant MS4A1 (Rituximab Biosimilar) dans ELISA. Convient pour Humain.

Aperçu rapide pour Recombinant MS4A1 (Rituximab Biosimilar) anticorps (ABIN7487776)

Antigène: MS4A1 (Rituximab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Mammalian Cells

Clonalité: Monoclonal

Conjugué: Cet anticorp MS4A1 (Rituximab Biosimilar) est non-conjugé

Application: ELISA

Classe de qualité: Research Grade

Détail du produit anti-MS4A1 (Rituximab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Rituximab Biosimilar - Anti-MS4A1 mAb

Attributs du produit: Antibody Type: IgG1

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG1

Information d'application

Restrictions: For Research Use only

Stockage

Buffer: PBS pH 7.5

Stock: 4 °C,-20 °C

Stockage commentaire: 4°C for short term, -20°C for long term

Détails sur MS4A1 (Rituximab Biosimilar)

Antigène: MS4A1 (Rituximab Biosimilar)

Classe de substances: Biosimilar

Sujet: Rituximab
Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein it triggers cell death. Rituximab is a medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers.